Cerulean Pharma (CERU) Granted Fast Track Designation for CRLX101 in ... StreetInsider.com “The Fast Track designation recognizes the serious unmet medical need of patients with metastatic renal cell carcinoma and the potential of CRLX101 to address this disease,” said Christopher D. T. Guiffre, Cerulean's President and Chief Executive Officer. CRLX101 Fast Tracked for Metastatic Renal Cell Carcinoma Monthly Prescribing Reference all 5 news articles »

...